EANS-Adhoc: Card Guard subsidiary LifeWatch Inc. Launches Next Generation Wireless LifeStar ACT ExTM with Advanced Holter Analysis and Storage
Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich.
Neue Produkte/LifeStar ACT EX
11.05.2009
Neuhausen am Rheinfall / Switzerland and Chicago / USA, May 12, 2009 - Card Guard AG's (SIX Swiss Exchange: CARDG) American subsidiary LifeWatch Services, Inc., the leading provider of wireless telemedicine services in the U.S., announces the launch of its next-generation wireless Ambulatory Cardiac Telemetry. The LifeStar ACT ExTM with advanced Holter analysis will broaden the utilization of ambulatory cardiac telemetry, add real-time auto-trigger and auto-send to the traditional Holter service model and allow the physician to use a single device for multiple purposes.
The launch of LifeWatch's first-to-market wireless LifeStar ACT Ex using its 3- channel ambulatory cardiac telemetry platform, boasts the ability to remotely retrieve up to 48 hours of digital Holter data for near real time analysis. With its 30 day storage capability, it can also provide a retrospective Holter analysis upon device retrieval for as much as a 7-day period. The clinical significance of this unique capability includes the following:
- Immediate notification of abnormal, life threatening arrhythmias using ACT auto-trigger, auto send features
- Data can be remotely retrieved using cellular technology for real-time analysis
- Aid in the accurate diagnosis and quantification of Atrial Fibrillation (AF) and other cardiac rhythm disturbances, inclusive of AF burden for physicians treating patients with AF and those patients who have had strokes with an unknown origin
- Detailed ECG analysis surrounding a particular arrhythmia event in order to accurately identify its origin and tailor a treatment plan specific to the patient
- Detailed ECG analysis includes ability to analyze the QT segment of the heart beat which can be an indicator of increased vulnerability for lethal arrhythmias and can result in loss of consciousness, and potentially sudden cardiac death
This innovation may obviate the need for emergency department evaluation and hospital admissions, thus fulfilling the promise of TeleHealth for outpatient diagnosis and management of patients with cardiac arrhythmias. The ACT Ex simplistic functionality increases the ease of use for patients for better compliance, while providing the most comprehensive cardiac monitoring solution in the market.
"Despite its very low diagnostic yield (6%), the 24-48 hour Holter test has been the predominant test of choice and utilized by most physicians for arrhythmia diagnosis and management. The ACT Ex, with its blended Holter analysis and auto-detect/auto-trigger capabilities allows for the same analysis with improved yield. Its ability to extend the monitoring period up to 7 days and potentially weeks at a time will dramatically improve diagnostic yield. Furthermore, the longer monitoring period allows for the accurate assessment of the patient's rhythm disturbance during the course of normal daily activities. Important information such as the adequacy of rate control during persistent AF, AF burden following an intervention such as the administration of an anti- arrhythmic medication or catheter or surgical ablation can be obtained," stated Harry Kopelman, M.D., LifeWatch Medical Advisory Board Chairman.
Dr. Yacov Geva, Chairman and CEO of Card Guard AG, stated, "Our mission is to develop the most accurate and convenient wireless patient monitoring technologies and clinical services in the industry that have the ability to capture and deliver critical data for faster time to treatment and higher diagnostic yield. The unique features of the ACT Ex were developed in consultation with our esteemed Medical Advisory Board".
Upcoming Card Guard Events
18 May 2009 Analysts' and Media conference Results Q1 2009
26 May 2009 Annual Shareholder Meeting of Card Guard AG in Zurich
About Card Guard AG
Card Guard AG, headquartered in Neuhausen am Rheinfall, Switzerland, is a leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless cardiac monitoring services. Card Guard services treat high-risk and chronically ill patients, health conscious consumers and wellness programs. Card Guard has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. Card Guard AG is the parent company of LifeWatch Services Inc., a leading US- based cardiac monitoring service provider, and LifeWatch Technologies Inc., a US-based manufacturer of telecardiology products. www.cardguard.com
About LifeWatch Corp.
LifeWatch is a wholly owned subsidiary of Card Guard AG, a leading healthcare technology and solutions provider listed on SIX Swiss Stock Exchange (CARDG). LifeWatch Corp., through its operating subsidiaries LifeWatch Services, Inc. and LifeWatch Technologies, Inc. (Instromedix) is an independent provider of ambulatory cardiac monitoring services and a manufacturer and distributor of ambulatory cardiac and vital signs monitoring devices in the United States. Its current services are used by physicians primarily to monitor patients who are suspected of having heart rhythm disorders, or cardiac arrhythmias, and its products are used by itself and by others in connection with providing cardiac monitoring services. For more information, visit: www.lifewatch.com. Sign-up for customized E-mail alerts and documentation requests is available at
http://www.cardguard.com/newsite/inner.asp?cat=38&type=2&lang=1&mal=y es
This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward- looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Card Guard AG has based these forward- looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward- looking statements. All forward-looking statements are based only on data available to Card Guard AG at the time of the issue of this press release. Card Guard AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF CARD GUARD AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF CARD GUARD AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF CARD GUARD AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM CARD GUARD AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.
Rückfragehinweis:
For further information please contact:
Kobi Ben Efraim
Chief Financial Officer
Tel +41 52 632 00 50 | Fax +41 52 632 00 51
Email kobibe@cardguard.com
Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12
Email cardguard@sensus.ch
Branche: Gesundheitsdienste
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market (Freiverkehr) / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / Freiverkehr